Abstracts tagged "Biologicals"

Abstract Number: 0903 • ACR Convergence 2020
Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset
Sabina Ciciriello¹, Tegan Smith², Geoffrey Littlejohn³, Kathleen Tymms⁴, David Mathers⁵, Helen Cooley⁶, Hedley Griffiths⁷, Catherine OSullivan² and Peter Youssef⁸, ¹Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ⁴Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁵Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁶Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁷Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, ⁸University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia
Background/Purpose: In Australia the cost of biologic/targeted synthetic DMARDs (b/tsDMARDs) for treatment of PsA is subsidized if the patient has documented high levels of clinical/laboratory…
Abstract Number: 1226 • ACR Convergence 2020
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
Roxanne Cooksey¹, Sinead Brophy¹, Muhammad Azizur¹, Jonathan Kennedy¹ and Ernest Choy², ¹Swansea University, Swansea, Wales, United Kingdom, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics. Etanercept biosimilar,…
Abstract Number: 1376 • ACR Convergence 2020
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Data on the impact of body weight and body mass index (BMI) on the response to biological disease-modifying anti-rheumatic drugs (bDMARDs) in axial spondyloarthritis…
Abstract Number: 1764 • ACR Convergence 2020
Disease Modifying Anti-rheumatic Drug and Biologic Therapy in Pregnancy: A Single-center Mixed Methods Study
Lauren Glick¹, Justin Shamis², Taneisha McGhie³ and Dharini Mahendira⁴, ¹University of Toronto, Toronto, ON, Canada, ²North York General Hospital, Toronto, ON, Canada, ³Cornwall University Hospital, Kingston, Saint Andrew, Jamaica, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Rheumatic diseases including rheumatoid arthritis, seronegative inflammatory arthritis and systemic lupus erythematosus can be associated with significant morbidity in women of child-bearing age. Both…
Abstract Number: 0003 • ACR Convergence 2020
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Quinn Pritchett¹, Rebecca Overbury¹, Dorota Lebiedz-Odrobina¹, Julie Thomas¹, Tawnie Braaten², Stacey Clardy¹, Marc Elgort³, Emily Spivak¹, Patricia Slev³, Lisa Peterson³ and Tracy Frech⁴, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, ³ARUP, Salt Lake City, UT, ⁴University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
Abstract Number: 0230 • ACR Convergence 2020
Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial
Nora G. Singer¹, Shalini V. Mohan², Jeffrey Yourish³, Jian Han², Michael Edwardes⁴ and Margaret Michalska³, ¹Case Western Reserve University and MetroHealth System, Cleveland, ²Genentech, South San Francisco, CA, ³Genentech, Inc., South San Francisco, ⁴Everest Clinical Research, Ontario, Canada
Background/Purpose: In patients with rheumatoid arthritis (RA), subcutaneous tocilizumab (TCZ-SC) is administered every 2 weeks (q2w) or every week (qw), based on the patient’s weight…
Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Laure Gossec¹, Philip Mease², Alice Gottlieb³, Deepak Assudani⁴, Jason Coarse⁵, Barbara Ink⁶ and Laura Coates⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Raleigh, NC, ⁶UCB Pharma, Slough, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…
Abstract Number: 0516 • ACR Convergence 2020
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
Sebastian Unizony¹, Shalini V. Mohan², Jian Han² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
Abstract Number: 0743 • ACR Convergence 2020
Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
William Robinson¹, Chun Wu², Sarah Hu², Sean Connolly² and Sumanta Mukherjee², ¹Stanford University School of Medicine, Stanford, CT, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: ACPAs are sensitive, highly specific markers of RA. Current tests cannot differentiate ACPA+ RA subtypes. Fine-specificity ACPAs (FS) can distinguish between ACPA+ RA subtypes…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Sebastian Unizony¹, Joseph Dang², Jian Han³, Margaret Michalska² and Jennie H. Best², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, ³Genentech, South San Francisco, CA
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
Abstract Number: 1427 • ACR Convergence 2020
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach
Allyson Egan¹, Pasupathy Sivasothy², Robin Gore³, Caroline Owen³, Marcos Del Martinez Pero⁴, Rachel Jones⁴, Lisa Willcocks⁴, Rona Smith⁴, Stella Burns⁴ and David Jayne⁵, ¹Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., London, United Kingdom, ²Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., Cambridge, England, United Kingdom, ³Department of Respiratory medicine, Addenbrooke's Hospital, Cambridge, Cambridge, United Kingdom, ⁴Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., Cambridge, ⁵Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: EGPA is a small vessel vasculitis characterized by the presence of tissue eosinophilia, necrotizing vasculitis and granulomatous inflammation1. In the randomized, placebo-controlled MIRRA trial…
Abstract Number: 1826 • ACR Convergence 2020
Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra Hahn², George Tsokos³, Peter Lipsky⁴, Robert Gordon⁵, Kaiyin Fei⁶, Kim Hung Lo⁷, Marc Chevrier⁸, Qing Zuraw⁹, Pamela Berry¹⁰, Chetan Karyekar¹⁰ and Shawn Rose¹¹, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²University of California Los Angeles, Encino, CA, ³Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ⁴RILITE Foundation, Charlottesville, VA, ⁵Janssen Research & Development, LLC, Chester Springs, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, Spring House, ⁸Janssen Research & Development, LLC, Collegeville, PA, ⁹Janssen Research & Development, LLC, Wayne, PA, ¹⁰Janssen Global Services, LLC, Horsham, PA, ¹¹Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Both IL-12 and IL-23 have been implicated in the pathogenesis of SLE. In a phase 2 study, treatment with the anti-IL-12/23 p40 monoclonal antibody…
Abstract Number: 0008 • ACR Convergence 2020
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
Akhil Sood¹, Arbi Galestanian¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].